Efficacy and safety of low dose Colchicine in patients with atherothrombotic brain infarction and gout or hyperuricemia
Not Applicable
- Conditions
- atherothrombotic brain infarction
- Registration Number
- JPRN-UMIN000041992
- Lead Sponsor
- Japanese Red Cross Kyoto Daini Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1.pre mRS more than 3 2.Have a potential cardiac source of embolism 3.suspect of arterial dissection. 4.unavailable to MRI. 5.Life expectancy less than 1 year. 6.Contraindicated for Colchicine. 7.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary efficacy endpoint is the first occurrence of an event of ischemic stroke recurrence during the first 12th month after treatment. The primary safety endpoint was to evaluate any adverse events and the Colchicine related side effects during the observation period.
- Secondary Outcome Measures
Name Time Method Myocardial infarction, or stroke, infection, and total mortality during the first 12th month after treatment.